You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEK1/2 inhibitor,

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma Trial in Memphis (Mirdametinib)

Recruiting
  • Low-Grade Glioma
  • +2 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 24, 2022

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

Arteriovenous Malformations Trial (Trametinib tablet)

Not yet recruiting
  • Arteriovenous Malformations
  • Trametinib tablet
  • (no location specified)
Oct 17, 2023

Advanced Solid Tumor (Phase 1), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) Trial in United States (IMM-1-104)

Recruiting
  • Advanced Solid Tumor (Phase 1)
  • +4 more
  • Duarte, California
  • +4 more
Feb 2, 2023

NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Phase I - Mirdametinib - Level 1
  • +4 more
  • (no location specified)
Jul 7, 2023

Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

Active, not recruiting
  • Gastrointestinal Cancer
  • New York, New York
  • +1 more
Nov 29, 2022

Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)

Active, not recruiting
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
  • Washington, District of Columbia
  • +4 more
Apr 1, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Dabrafenib Mesylate
  • +2 more
  • Atlanta, Georgia
  • +6 more
Nov 30, 2022

Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer Trial in Nashville (Atezolizumab, Cobimetinib,

Terminated
Has Results
  • Stage III Breast Cancer
  • +6 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Aug 10, 2021

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +11 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Mar 22, 2022

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

Recruiting
  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • +2 more
  • Futibatinib and Binimetinib
  • Santa Monica, California
  • +2 more
Jun 2, 2022

Metastatic Uveal Melanoma Trial in Philadelphia (Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766)

Recruiting
  • Metastatic Uveal Melanoma
  • Defactinib Hydrochloride
  • +2 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 23, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma Trial in Worldwide (Binimetinib Oral Tablet

Not yet recruiting
  • Adamantinous Craniopharyngioma
  • Recurrent Adamantinomatous Craniopharyngioma
  • Binimetinib Oral Tablet [Mektovi]
  • Aurora, Colorado
  • +17 more
Nov 28, 2022

Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen

Not yet recruiting
  • Metastatic Endometrial Carcinoma
  • +7 more
  • Biopsy
  • +5 more
  • (no location specified)
Jan 18, 2023

EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)

Recruiting
  • EGFR NP_005219.2:p.S492R
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

MPNST, NF1, Sarcoma Trial in United States (Selumetinib)

Not yet recruiting
  • MPNST
  • +2 more
  • Birmingham, Alabama
  • +13 more
Jun 29, 2022

Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) Trial in United States (Mirdametinib (PD-0325901) oral capsule or

Active, not recruiting
  • Plexiform Neurofibroma
  • Neurofibromatosis Type 1 (NF1)
  • Mirdametinib (PD-0325901) oral capsule or dispersible tablet
  • Birmingham, Alabama
  • +49 more
Nov 17, 2022

Lungcancer Trial in Canada (Binimetinib, Pemetrexed, Carboplatin)

Completed
  • Lungcancer
  • Edmonton, Alberta, Canada
  • +3 more
Apr 1, 2021

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 Trial in

Not yet recruiting
  • Locally Advanced Pancreatic Adenocarcinoma
  • +6 more
  • Biopsy
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 26, 2022

Advanced Malignant Solid Tumor Trial in United States (Adavosertib, Carboplatin, Everolimus)

Completed
Has Results
  • Advanced Malignant Solid Neoplasm
  • Aurora, Colorado
  • +7 more
Apr 11, 2022

Solid Tumor, Colorectal Cancer Trial in Oxford (PF-02341066, PD-0325901, Binimetinib)

Completed
Has Results
  • Solid Tumor
  • Colorectal Cancer
  • Oxford, United Kingdom
    Oxford University Hospital NHS Trust
Jun 14, 2021